奥马珠单抗治疗阿司匹林哮喘合并中耳炎和鼻窦炎一例

打开文本图片集

摘要：奥马珠单抗是一种重组人源化单克隆抗体，为抗IgE靶向生物制剂，是全球首个获批治疗中至重度支气管哮喘的靶向治疗药物。本文对1例阿司匹林哮喘伴分泌性中耳炎及鼻窦炎患者进行回顾性分析，探讨奥马珠单抗在治疗哮喘及其合并症中的价值，为临床实践提供依据。

关键词：奥马珠单抗；哮喘；鼻窦炎；中耳炎

中图分类号： R593.1 文献标志码： B 文章编号：1000-503X（2023）04-0699-04

DOI：10.3881/j.issn.1000-503X.15265

Omalizumab Treats Aspirin-Induced Asthma Complicated With

Nasosinusitis and Otitis Media：Report of One Case

TANG Rui1，LEI Shubin2，WANG Yi3

1Department of Allergy，Beijing Key Laboratory of Precision Medicine for Diagnosis and Treatment of Allergic Disease，

National Clinical Research Center for Dermatologic and Immunologic Diseases，

PUMC Hospital，CAMS and PUMC，Beijing 100730，China

2Eight-Year Program of Clinical Medicine，CAMS and PUMC，Beijing 100730，China

3Department of Otolaryngology and Head and Neck Surgery，PUMC Hospital，CAMS and PUMC，Beijing 100730，China

Corresponding author：WANG Yi Tel：010-69151601，E-mail：ywin6727@yahoo.com

ABSTRACT：Omalizumab，as a biological agent targeting IgE，is a recombinant humanized monoclonal antibody and the first targeted drug approved for treating moderate-to-severe bronchial asthma.By reviewing one case of aspirin-induced asthma complicated with nasosinusitis and otitis media，we discussed the value of omalizumab in the treatment of asthma and its complications，aiming to provide a reference for clinical practice.

Key words：omalizumab；asthma；nasosinusitis；otitis media

Acta Acad Med Sin，2023，45（4）：699-702

奥马珠单抗是一种重组人源化单克隆抗体，为抗IgE靶向生物制剂，是全球首个获批治疗中至重度支气管哮喘的靶向治疗药物，目前已证实奥马珠单抗可有效缓解哮喘发作期症状、减低哮喘发作频率、提高患者生活质量［1-2］。（剩余4631字）